Clinical Trial Accrual

## Overcoming Barriers to Advancing Cancer Treatment

ClinicalPath

Across ClinicalPath (formerly Via Oncology) customer institutions with a strong focus on research, we see an overall accrual rate of 10% (2x the national average) and when a trial is available, patient accrual is 20% (4x the national average).

Challenges

- Clinical trials are critical to the development of new cancer therapies, but so much stands in the way.
- While clinical trial treatment is considered on-guideline and may result in a lower financial burden to the patient, the **national average of cancer patients accrued to clinical trials is only 2-4%.**[i,ii] This results in early study closure and delays in creating life-saving drugs.
- Studies have identified barriers at multiple levels: [iii]
    - At the institution level, defining the optimal set of clinical trials for your patient population.
    - At the provider level, awareness of trials and accruing patients appropriately.
    - At the patient level, access to trials, based on their treatment site. Trials at community sites may be more restricted than for patients treated at academic centers.

In pediatric populations where clinical trial accrual rates are greater than 50%, **mortality has been decreasing** since 1970 by 2.6% per year.[iv]

Opportunity

Institutions with a robust clinical trial program can benefit from:

- Reimbursement for participating sites, with industry-sponsored trials providing up to **$15,000 per patient enrolled.**[v]
- A **competitive advantage**, attracting patients interested in accessing precision medicine options that may not be available at their current institution.
- Accreditation as an NCI Comprehensive Cancer Center, including the opportunity to apply for up to **$1.5m in research funding.**[vi]

How Elsevier's ClinicalPath Can Help Your Institution

For your providers:

- View **institution-specific** clinical trials, ahead of standard of care recommendations, making it easier to identify patients for screening.

- View **patient-specific** clinical trials, because trials are placed at specific branches of the pathway based on trial inclusion/exclusion criteria.

- **Links to trial documents** from within the workflow for easy access to additional information.

For your patients:

- **Visibility into trials across your institution**, including at community and academic sites.

- Increased likelihood of accrual (over 70% of cancer patients indicate they would be interested in participating in a trial). [vii]

- Access new cancer therapies **closer to home**, increasing compliance.

For your institution:

- Get **detailed analytics** on patient accrual rates, trial availability and patient presentation characteristics, at the site and provider level — enabling your leadership team to make informed decisions on the optimal trials for your organization.

- Support **workflow coordination** between physicians and research teams through secure messaging. ClinicalPath also interfaces with trial management systems for automated updating of trial status.

A multi-site oncology practice leveraged the ClinicalPath clinical trial functionality to raise trial participation for lung cancer patients to 25%, more than 5x the national average.

Resources

i   Clinical Trial Accrual: Obstacles and Opportunities, Frontiers in Oncology, April 25, 2016, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843106/

ii   Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies, American Society of Clinical Oncology Educational Book, July 3, 2017, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495113/

iii   The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations, Journal of Oncology Practice, November 2013, https://www.ncbi.nlm.nih.gov/pubmed/24130252

iv   Understanding clinical trials in childhood cancer, Journal of Paediatrics and Child Health, March, 2006, https://www.ncbi.nlm.nih.gov/pubmed/19030270/

v   A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program, 3: Operations, Oversight, and Funding of Cancer Clinical Trials, 2010, https://www.ncbi.nlm.nih.gov/books/NBK220383/

vi   Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30), National Institutes of Health, accessed online September 2019, https://grants.nih.gov/grants/guide/pa-files/PAR-17-095.html

vii   Clinical Trials in Immunotherapy, Association of Community Cancer Centers, Jul 27, 2017, https://www.accc-cancer.org/home/learn/immunotherapy/resource-detail/Clinical-Trials-in-Immunotherapy

To learn more, visit Elsevier.com/clinicalpath

ELSEVIER

ClinicalPath